global
polio
erad
initi
laboratori
diagnosi
play
critic
role
isol
identifi
polioviru
pv
stool
sampl
acut
flaccid
paralysi
afp
case
recent
year
reestablish
pv
circul
countri
pv
previous
elimin
occur
decreas
herd
immun
possibl
due
poor
vaccin
coverag
monitor
vulner
countri
pv
circul
surveil
neutralizingantibodi
titer
pv
suscept
popul
essenti
end
game
polio
erad
program
studi
develop
pv
neutral
test
type
pv
pseudovirus
determin
neutralizingantibodi
titer
pv
human
serum
sampl
test
neutralizingantibodi
titer
pv
could
determin
within
day
autom
interpret
luciferas
signal
without
use
infecti
pv
strain
valid
pseudoviru
pv
neutral
test
human
serum
sampl
collect
wide
rang
age
group
age
year
comparison
convent
neutral
test
found
good
correl
neutralizingantibodi
titer
determin
test
result
suggest
pseudoviru
pv
neutral
test
would
serv
safe
simpl
procedur
measur
neutralizingantibodi
titer
pv
global
polio
erad
initi
laboratori
diagnosi
play
critic
role
isol
identifi
polioviru
pv
stool
sampl
acut
flaccid
paralysi
afp
case
surveil
pv
circul
world
health
organ
global
polio
laboratori
network
pv
isol
identif
perform
nation
polio
laboratori
cell
cultur
system
follow
differenti
isol
oral
pv
vaccin
opv
relat
pv
vaccinederiv
pv
vdpv
wildtyp
pv
isol
sever
method
region
refer
laboratori
surveil
pv
essenti
monitor
progress
pv
erad
countri
pv
endem
countri
mainten
poliofre
statu
countri
pv
endem
prevent
circul
import
pv
vdpv
countri
pv
endem
proper
vaccin
campaign
end
game
erad
program
surveil
seropreval
pv
suscept
popul
essenti
monitor
vulner
pv
circul
pvfree
countri
sustain
pvfree
statu
seroconvers
rate
countri
pv
endem
evalu
effect
vaccin
strategi
laboratori
neutralizingantibodi
titer
determin
convent
pv
neutral
test
cpnt
use
suscept
cell
cultur
system
infecti
challeng
viru
characterist
requir
cpnt
follow
use
infecti
viru
usual
opv
strain
use
ii
expertis
personnel
observ
cytopath
effect
cpe
inocul
cell
iii
extend
time
result
day
cultur
japan
surveil
neutral
antibodi
pv
perform
everi
year
sinc
serum
sampl
healthi
volunt
individu
prefectur
wide
rang
age
year
base
cpnt
prefectur
laboratori
http
idscnihgojpyosoku
consid
biosafeti
expertis
requir
test
pv
neutral
test
safer
simpler
cpnt
would
desir
end
game
erad
program
present
studi
develop
novel
pv
neutral
test
use
nonselfprolifer
pv
pseudoviru
encapsid
luciferaseencod
pv
replicon
pv
capsid
protein
pseudoviru
pv
neutral
test
ppnt
neutralizingantibodi
titer
determin
base
luciferas
signal
inocul
cell
within
day
result
suggest
ppnt
would
serv
safe
simpl
procedur
measur
neutralizingantibodi
titer
pv
cell
human
embryon
kidney
cell
cultur
monolay
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
fc
vero
cell
african
green
monkey
kidney
cell
cultur
monolay
eagl
minimum
essenti
medium
emem
supplement
bovin
serum
albumin
bsa
fraction
v
sigma
rd
cell
use
titrat
pv
ppnt
vero
cell
use
ppnt
cell
use
product
pv
pseudovirus
pv
pseudovirus
encapsid
luciferaseencod
pv
replicon
pv
capsid
protein
deriv
mahoney
saukett
prepar
report
previous
see
construct
type
pv
capsid
protein
express
vector
prepar
pv
pseudovirus
human
sera
collect
healthi
volunt
age
year
inform
consent
experi
perform
present
studi
approv
committe
ethic
regul
nation
institut
infecti
diseas
japan
gener
method
molecular
clone
escherichia
coli
strain
stratagen
use
prepar
plasmid
ligat
dna
fragment
perform
use
quick
ligat
kit
new
england
biolab
pcr
perform
use
kod
plu
dna
polymeras
toyobo
revers
transcriptionpcr
rtpcr
perform
use
revertra
plu
kit
toyobo
dna
sequenc
perform
use
bigdy
termin
cyclesequenc
readyreact
kit
appli
biosystem
analyz
genet
analyz
appli
biosystem
construct
type
pv
capsid
express
vector
construct
express
vector
type
pv
capsid
protein
fuse
enhanc
green
fluoresc
protein
egfp
gene
pv
capsid
protein
code
region
saukett
pcr
measur
express
level
pv
capsid
protein
egfp
code
region
amplifi
pcr
primer
fusion
type
pv
capsid
protein
code
region
primer
fusion
type
pv
capsid
protein
code
region
hindiii
site
primer
underlin
use
clontech
templat
type
pv
capsid
protein
code
region
amplifi
rtpcr
primer
xbai
site
underlin
use
viral
genom
rna
templat
type
pv
capsid
protein
code
region
amplifi
rtpcr
primer
bamhi
site
underlin
use
viral
genom
rna
saukett
templat
next
dna
fragment
egfp
pv
capsid
protein
code
region
fuse
pcr
use
primer
type
pv
hindiii
xbai
site
underlin
primer
type
pv
hindiii
bamhi
site
underlin
fuse
dna
fragment
clone
express
vector
kind
gift
koji
sakai
aid
research
center
nation
institut
infecti
diseas
tokyo
japan
follow
digest
hindiii
xbai
type
pv
hindiii
bamhi
type
pv
result
plasmid
name
saukett
respect
use
pv
capsid
protein
express
vector
product
pv
pseudovirus
prepar
pv
pseudoviru
pv
pseudovirus
prepar
report
previous
modif
briefli
sixwel
plate
falcon
confluent
monolay
cell
transfect
g
correspond
pv
capsid
express
vector
per
well
use
lipofectamin
reagent
invitrogen
cell
incub
ml
dmem
supplement
fc
per
well
h
rna
transcript
pv
replicon
obtain
use
ribomax
largescal
rna
product
kit
promega
drailinear
dna
ppvfluc
mc
includ
pv
replicon
base
mahoney
firefli
luciferas
gene
instead
capsidcod
region
templat
rna
transcript
transfect
monolay
cell
transient
express
pv
capsid
protein
h
posttransfect
use
lipofectamin
rnaimax
reagent
invitrogen
cell
harvest
h
posttransfect
rna
transcript
cell
show
cpe
store
cpnt
cpnt
perform
accord
standard
procedur
recommend
modif
first
l
human
serum
sampl
standard
antipv
sera
posit
control
dilut
emem
dilut
dilut
seri
prepar
emem
supplement
bsa
result
dilut
l
dilut
sera
emem
supplement
bsa
ad
three
plate
well
one
dilut
plate
total
well
one
dilut
plate
next
l
type
pv
sabin
strain
cell
cultur
infect
dose
ccid
ad
well
plate
plate
serotyp
pv
total
plate
incub
h
incub
l
vero
cell
suspens
emem
supplement
bsa
cell
ad
well
plate
plate
incub
day
neutralizingantibodi
titer
serum
type
pv
determin
endpoint
serum
inhibit
pv
infect
observ
cpe
inocul
cell
ppnt
ppnt
first
l
human
serum
sampl
standard
antipv
sera
posit
control
dilut
dmem
supplement
fc
dilut
dilut
seri
made
result
dilut
l
dilut
sera
dmem
supplement
fc
mock
treatment
neg
control
ad
three
plate
well
one
dilut
plate
total
well
one
dilut
plate
catalog
greiner
bioon
next
l
type
pv
pseudoviru
solut
infecti
unit
iu
ad
well
plate
plate
serotyp
pv
pseudoviru
total
plate
plate
subject
centrifug
g
platespin
kubota
centrifug
plate
seal
film
microamp
appli
biosystem
incub
overnight
incub
l
rd
cell
suspens
dmem
supplement
fc
cell
ad
well
plate
plate
incub
h
luciferas
activ
infect
cell
measur
h
postinfect
pi
steadyglo
luciferas
assay
system
promega
use
arvo
x
luminomet
perkinelm
accord
manufactur
instruct
pv
pseudoviru
infect
calcul
percentag
luciferas
activ
infect
cell
luciferas
activ
mocktreat
cell
taken
mean
signal
cp
standard
deviat
mean
neutral
antibodi
titer
serum
type
pv
determin
highest
dilut
serum
inhibit
type
pv
pseudoviru
infect
respect
establish
pv
neutral
test
use
pv
pseudoviru
produc
type
pv
pseudovirus
luciferaseencod
pv
replicon
type
pv
capsid
protein
respect
previou
studi
establish
product
system
type
pv
pseudoviru
mahoney
capsid
protein
present
studi
construct
pv
capsid
express
vector
express
capsid
protein
saukett
express
vector
luciferaseencod
pv
replicon
obtain
type
pv
pseudovirus
high
titer
iu
per
ml
respect
compar
type
pv
pseudoviru
iu
per
ml
perform
serial
passag
type
pv
pseudovirus
produc
attempt
isol
infecti
viru
might
emerg
prepar
iu
pv
pseudovirus
passag
cell
previous
perform
type
pv
pseudoviru
infecti
viru
isol
type
pv
pseudovirus
data
shown
analyz
specif
neutral
pv
pseudovirus
use
typespecif
standard
antipv
sera
optim
titer
pv
pseudoviru
neutral
test
fig
differ
titer
pv
pseudovirus
iu
incub
standard
antipv
sera
monkey
antisera
contain
unit
neutralizingantibodi
titer
l
type
pv
sabin
strain
neutral
perform
overnight
accord
condit
use
cpnt
standard
antipv
sera
show
specif
neutral
correspond
type
pv
pseudoviru
rang
titer
pv
pseudovirus
similar
neutral
curv
observ
rang
titer
pv
pseudovirus
serotyp
neutral
activ
standard
serum
type
pv
pseudoviru
lower
type
type
pv
pseudovirus
luciferas
signal
inocul
cell
iu
pv
pseudovirus
cp
cp
cp
standard
deviat
mean
respect
rang
titer
pv
pseudovirus
iu
consist
result
obtain
specif
neutral
curv
therefor
determin
iu
pv
pseudovirus
optim
titer
give
consist
result
ppnt
summari
procedur
ppnt
interpret
shown
fig
measur
neutralizingantibodi
titer
pv
human
sera
cpnt
ppnt
perform
ppnt
human
serum
sampl
compar
result
obtain
cpnt
ppnt
reciproc
highest
dilut
serum
show
valu
equal
less
threshold
valu
determin
neutral
antibodi
titer
eg
type
fig
threshold
valu
type
pv
determin
comparison
result
obtain
cpnt
give
antipv
neutralizingantibodyposit
rate
sampl
percentag
sampl
show
neutralizingantibodi
titer
closest
determin
cpnt
fig
background
signal
test
correspond
approxim
pv
pseudoviru
infect
standard
deviat
therefor
could
set
threshold
valu
pv
pseudoviru
infect
type
pv
high
fluctuat
near
background
level
accord
criteria
threshold
valu
type
pv
set
pv
pseudoviru
infect
respect
threshold
valu
observ
good
correl
neutralizingantibodi
titer
determin
cpnt
ppnt
r
type
pv
respect
fig
final
compar
neutralizingantibodi
titer
determin
cpnt
ppnt
among
differ
age
group
fig
type
pv
distribut
neutralizingantibodi
titer
consist
cpnt
ppnt
age
group
howev
distribut
titer
type
pv
show
differ
profil
cpnt
ppnt
lower
titer
young
age
group
year
old
higher
titer
elderli
age
group
year
old
ppnt
suggest
antityp
pv
antibodi
differ
properti
among
age
group
studi
develop
novel
pv
neutral
test
use
pv
pseudovirus
instead
infecti
pv
strain
pseudotyp
virus
especi
envelop
virus
requir
high
biosafeti
level
contain
eg
sever
acut
respiratori
syndrom
coronaviru
sarscov
lyssavirus
nipah
viru
highli
pathogen
avian
influenza
virus
wide
use
neutral
test
safeti
advantag
ppnt
compar
cpnt
follow
biosafeti
ppnt
use
nonselfprolifer
pv
pseudoviru
versu
infecti
pv
strain
ii
simplic
procedur
autom
luciferas
assay
interpret
versu
observ
requir
expertis
iii
shorten
time
result
day
versu
day
moreov
ppnt
requir
less
human
serum
requir
cpnt
l
versu
l
thu
could
contribut
save
preciou
human
serum
resourc
use
biolog
test
end
game
polio
erad
program
biosafeti
reduc
burden
laboratori
test
would
import
area
polio
endem
observ
good
correl
overal
result
obtain
cpnt
ppnt
type
pv
pseudoviru
neutral
test
threshold
valu
arbitrarili
set
rang
gener
gave
result
good
correl
obtain
convent
test
especi
determin
neutralizationantibodyposit
rate
finetun
threshold
valu
might
benefit
link
result
obtain
differ
neutral
method
eg
suppress
cpe
could
aris
infecti
unit
viru
versu
overal
suppress
pseudoviru
infect
threshold
valu
therefor
set
threshold
valu
ppnt
rang
valu
examin
type
pv
give
antibodyposit
rate
closest
obtain
cpnt
fig
pv
pseudovirus
capsid
protein
deriv
differ
strain
serotyp
eg
capsid
protein
sabin
strain
versu
wildtyp
strain
might
differ
finetun
threshold
valu
part
depend
variat
antigen
properti
set
human
sera
examin
without
absolut
standard
neutral
antibodi
herd
immun
requir
pv
elimin
predict
circul
model
depend
level
hygien
neutralizingantibodi
titer
consid
protect
effect
paralyt
poliomyel
review
refer
therefor
wide
rang
threshold
valu
type
pv
type
type
ppnt
could
practic
accept
estim
antibodyposit
rate
accuraci
within
determin
cpnt
use
type
pv
pseudovirus
capsid
protein
mahoney
saukett
respect
ppnt
pv
strain
virul
current
use
antigen
inactiv
pv
vaccin
ipv
pv
consist
serotyp
although
antigen
variat
could
occur
within
serotyp
long
circul
year
therefor
evalu
neutral
antibodi
wildtyp
pv
strain
pv
pseudovirus
would
benefit
use
infecti
pv
vaccin
strain
neutralizingantibodi
titer
type
pv
overal
result
consist
cpnt
ppnt
fig
howev
agedepend
differ
distribut
titer
lower
titer
younger
group
higher
titer
elderli
group
ppnt
fig
japan
poliomyel
outbreak
caus
wildtyp
strain
mainli
occur
total
report
case
date
introduct
opv
therefor
plausibl
sera
elderli
group
year
old
birth
year
higher
neutral
activ
wildtyp
strain
vaccin
strain
low
titer
type
pv
observ
ppnt
younger
group
neutral
curv
pv
pseudovirus
human
serum
sampl
threshold
level
determin
neutralizingantibodi
titer
shown
dot
line
type
pv
respect
neutralizingantibodi
titer
circl
type
pv
respect
bottom
origin
data
neutral
curv
shown
top
well
show
highest
dilut
threshold
valu
two
line
measur
circl
well
show
highest
dilut
threshold
valu
measur
indic
arrow
type
pv
pseudoviru
suggest
antibodi
induc
opv
appar
higher
titer
vaccin
strain
parent
mahoney
strain
type
attenu
strain
chat
standard
serum
monkey
antisera
rais
sabin
strain
also
show
rel
low
neutral
activ
type
pv
pseudoviru
compar
type
pv
pseudovirus
fig
differ
level
neutralizingantibodi
titer
type
pv
strain
might
arisen
neutralizingantibodyposit
rate
sampl
determin
threshold
valu
shown
graph
threshold
valu
show
neutralizingantibodyposit
rate
closest
obtain
cpnt
highlight
color
type
pv
green
blue
type
pv
respect
b
scatter
plot
neutralizingantibodi
titer
obtain
cpnt
ppnt
threshold
valu
use
ppnt
type
pv
respect
number
serum
sampl
correspond
spot
visual
size
circl
along
number
sampl
spot
one
sampl
spot
regress
line
red
confid
interv
green
predict
interv
blue
analys
shown
fig
comparison
neutralizingantibodi
titer
obtain
cpnt
ppnt
differ
age
group
distribut
neutralizingantibodi
titer
obtain
cpnt
ppnt
indic
age
group
shown
number
serum
sampl
examin
age
group
shown
graph
parenthes
threshold
valu
ppnt
type
pv
respect
part
differ
epitop
strain
recogn
antibodi
report
induc
opv
ipv
antigen
site
respect
nevertheless
enigmat
distribut
neutralizingantibodi
titer
young
age
group
year
old
show
slight
differ
result
obtain
cpnt
ppnt
contrast
age
group
age
group
belong
postopv
introduct
era
thu
properti
antigen
seem
major
determin
caus
differ
suggest
transit
antibodi
properti
occur
longterm
immun
memori
summari
develop
pseudoviru
neutral
test
measur
neutralizingantibodi
titer
pv
human
serum
ppnt
would
serv
safe
simpl
rapid
test
serosurveil
pv
